Henry Schein (NASDAQ:HSIC) Announces Earnings Results

Key Points

• Henry Schein beat quarterly EPS expectations, reporting $1.56 per share versus the $1.36 consensus estimate. Revenue rose 4.0% year over year to $3.47 billion, slightly below analysts’ $3.48 billion forecast.
• U.S. dental merchandise sales increased 8.6%, while adjusted EPS grew 19.1% and the non-GAAP operating margin expanded to 8.03%. Management said its value-creation program remains on track to generate more than $200 million in operating-income improvement.
• 2026 non-GAAP EPS guidance was raised to $5.50–$5.56 from $5.29–$5.39, supported by stronger underlying performance and a $0.19-per-share tariff-refund benefit. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $93.27.

Henry Schein (NASDAQ:HSIC - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.20, Zacks reports. The business had revenue of $3.47 billion during the quarter, compared to analysts' expectations of $3.48 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%. The business's quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.38 EPS.

Here are the key takeaways from Henry Schein's conference call:

• U.S. dental merchandise sales rose 8.6%, including 7% internal local-currency growth, driven primarily by volume and claimed market-share gains among private practices and emerging DSOs.
• Adjusted non-GAAP diluted EPS increased 19.1% to $1.37, while non-GAAP operating margin expanded 20 basis points to 8.03%; management said its value-creation program remains on track to deliver more than $200 million of operating-income improvement, including a $125 million run rate by year-end 2026.
• Henry Schein raised 2026 non-GAAP EPS guidance to $5.50-$5.56 from $5.29-$5.39 and expects adjusted EBITDA growth in the high single digits, citing stronger underlying performance and a $0.19-per-share tariff-refund benefit.
• Management plans targeted fourth-quarter investments in customer acquisition, share of wallet, company-owned and exclusive products, and cloud-based practice-management software, while continuing share repurchases; it bought back $125 million of stock in the quarter and had approximately $330 million remaining under authorization.
• The U.S. dental market and patient traffic were described as stable, but discretionary procedures showed some pressure from out-of-pocket costs; medical growth was also restrained by weaker point-of-care diagnostic and flu/COVID vaccine demand, partly offset by 11.4% growth in Home Solutions.

Henry Schein Stock Performance

Shares of Henry Schein stock traded down $1.83 during trading on Tuesday, reaching $84.79. The company's stock had a trading volume of 309,883 shares, compared to its average volume of 1,318,688. The company has a 50-day moving average price of $86.49 and a two-hundred day moving average price of $81.15. The firm has a market cap of $9.45 billion, a PE ratio of 24.67, a P/E/G ratio of 1.53 and a beta of 0.84. Henry Schein has a fifty-two week low of $68.00 and a fifty-two week high of $92.18. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Analyst Ratings Changes

Several equities research analysts recently weighed in on HSIC shares. Weiss Ratings upgraded Henry Schein from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, August 21st. Barrington Research set a $104.00 price objective on shares of Henry Schein in a report on Wednesday, August 5th. BMO Capital Markets assumed coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They set a "market perform" rating and a $85.00 price objective for the company. Piper Sandler upped their target price on shares of Henry Schein from $91.00 to $95.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Finally, BTIG Research increased their target price on shares of Henry Schein from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, August 19th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $93.27.

About Henry Schein

Henry Schein, Inc NASDAQ: HSIC is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.